SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
SRC 家族激酶 (SFK) 抑制剂达沙替尼通过抑制 Treg 细胞转化和增殖来提高 NSCLC 模型中抗 PD-1 的抗肿瘤活性
期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.3
doi:10.1136/jitc-2020-001496
Esther Redin, Irati Garmendia, Teresa Lozano, Diego Serrano, Yaiza Senent, Miriam Redrado, Maria Villalba, Carlos E De Andrea, Francisco Exposito, Daniel Ajona, Sergio Ortiz-Espinosa, Ana Remirez, Cristina Bertolo, Cristina Sainz, Juana Garcia-Pedrero, Ruben Pio, Juan Lasarte, Jackeline Agorreta, Lu